State Street’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-3,758
Closed -$32.3K – 4414
2024
Q1
$32.3K Hold
3,758
– – ﹤0.01% 4228
2023
Q4
$13.2K Hold
3,758
– – ﹤0.01% 4378
2023
Q3
$13.4K Hold
3,758
– – ﹤0.01% 4482
2023
Q2
$21.9K Hold
3,758
– – ﹤0.01% 4583
2023
Q1
$142K Hold
3,758
– – ﹤0.01% 4189
2022
Q4
$112K Hold
3,758
– – ﹤0.01% 4339
2022
Q3
$126K Hold
3,758
– – ﹤0.01% 4368
2022
Q2
$150K Hold
3,758
– – ﹤0.01% 4340
2022
Q1
$198K Buy
3,758
+110
+3% +$5.53K ﹤0.01% 4390
2021
Q4
$202K Hold
3,648
– – ﹤0.01% 4349
2021
Q3
$282K Hold
3,648
– – ﹤0.01% 4226
2021
Q2
$473K Buy
+3,648
New +$505K ﹤0.01% 3878

Other funds holding TCON

State Street's TCON Position: Q2 2024 in Review

State Street sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 3,758 shares — an estimated $32.3K sold.

State Street first reported a position in TCON in Q2 2021 and held it in 12 quarters. The position peaked at $473K in Q2 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • State Street reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • State Street sold 3,758 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $32.3K.
  • State Street first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • State Street's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $473K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.